Picture of Phil Cole
Philip A. Cole, M.D., Ph.D.
Professor of Medicine and Biological Chemistry and Molecular Pharmacology

Our research involves the chemical biology of protein post-translational modifcations (PTMs) in the context of signaling, epigenetics, and cancer.  We develop and apply chemical approaches including protein semisynthesis and small molecule probes to the study of protein phosphorylation, acetylation, ubiquitination, and other PTMs in enzymes and cellular networks. 

Phil Cole graduated from Yale University with a B.S. in Chemistry in 1984 and then spent a year as a Churchill Scholar at the University of Cambridge.  Cole went on to obtain M.D. and Ph.D. degrees from Johns Hopkins where he pursued research in bioorganic chemistry in 1991.  Cole then entered clinical and post-doctoral training at Brigham and Women's Hospital and Harvard Medical School prior to joining Rockefeller University in 1996 as a junior lab head.  In 1999, Cole returned to Johns Hopkins as professor and director of pharmacology where he served until 2017, when he moved to Harvard Medical School and Brigham and Women's Hospital as professor of medicine and biological chemistry and molecular pharmacology.  His research interests are in the area of chemical biology, protein post-translational modifications, cell signaling, and epigenetics.

 

Research:

Our research involves the chemical biology of protein post-translational modifcations (PTMs) in the context of signaling, epigenetics, and cancer.  We develop and apply chemical approaches including protein semisynthesis and small molecule probes to the study of protein phosphorylation, acetylation, ubiquitination, and other PTMs in enzymes and cellular networks.  We are currently investigating the functions, regulation, and mechanisms of PTEN lipid phosphatase, Akt protein kinase, NEDD4 ubiquitin ligases, LSD1 histone demethylase, HDAC1 deacetylase, the CoREST complex, and p300/CBP acetyltransferase.  We strive to translate our findings in signaling and epigenetics to identify novel therapeutic opportunities for the treatment of cancer and other diseases.

Address: 

New Research Building

77 Avenue Louis Pasteur

Room 168C

Boston, MA 02115

Publications View
Inhibiting the coregulator CoREST impairs Foxp3+ Treg function and promotes antitumor immunity.
Authors: Authors: Xiong Y, Wang L, Di Giorgio E, Akimova T, Beier UH, Han R, Trevisanut M, Kalin JH, Cole PA, Hancock WW.
J Clin Invest
View full abstract on Pubmed
Lysine-specific demethylase 1 mediates AKT activity and promotes epithelial-mesenchymal transition in PIK3CA mutant colorectal cancer.
Authors: Authors: Miller SA, Policastro RA, Savant SS, Sriramkumar S, Ding N, Lu X, Mohammad HP, Cao S, Kalin JH, Cole PA, Zentner GE, O'Hagan HM.
Mol Cancer Res
View full abstract on Pubmed
Editorial overview: Biological catalysis at the cross-roads of signaling and metabolism.
Authors: Authors: Cole PA, Mattevi A.
Curr Opin Struct Biol
View full abstract on Pubmed
Re-programing Chromatin with a Bifunctional LSD1/HDAC Inhibitor Induces Therapeutic Differentiation in DIPG.
Authors: Authors: Anastas JN, Zee BM, Kalin JH, Kim M, Guo R, Alexandrescu S, Blanco MA, Giera S, Gillespie SM, Das J, Wu M, Nocco S, Bonal DM, Nguyen QD, Suva ML, Bernstein BE, Alani R, Golub TR, Cole PA, Filbin MG, Shi Y.
Cancer Cell
View full abstract on Pubmed
Comparative analysis of the catalytic regulation of NEDD4-1 and WWP2 ubiquitin ligases.
Authors: Authors: Jiang H, Thomas SN, Chen Z, Chiang CY, Cole PA.
J Biol Chem
View full abstract on Pubmed
CREB Promotes Beta Cell Gene Expression by Targeting Its Coactivators to Tissue-Specific Enhancers.
Authors: Authors: Van de Velde S, Wiater E, Tran M, Hwang Y, Cole PA, Montminy M.
Mol Cell Biol
View full abstract on Pubmed
Evaluation of a High-risk Patient Reminder System for Colonoscopy Surveillance.
Authors: Authors: Grimes AD, Cole PA, Grimes RW.
Am J Health Behav
View full abstract on Pubmed
Analysis of Site-Specific Phosphorylation of PTEN by Using Enzyme-Catalyzed Expressed Protein Ligation.
Authors: Authors: Henager SH, Henriquez S, Dempsey DR, Cole PA.
Chembiochem
View full abstract on Pubmed
MITF Expression Predicts Therapeutic Vulnerability to p300 Inhibition in Human Melanoma.
Authors: Authors: Kim E, Zucconi BE, Wu M, Nocco SE, Meyers DJ, McGee JS, Venkatesh S, Cohen DL, Gonzalez EC, Ryu B, Cole PA, Alani RM.
Cancer Res
View full abstract on Pubmed
Combination Targeting of the Bromodomain and Acetyltransferase Active Site of p300/CBP.
Authors: Authors: Zucconi BE, Makofske JL, Meyers DJ, Hwang Y, Wu M, Kuroda MI, Cole PA.
Biochemistry
View full abstract on Pubmed